Clinical referenceGuideUpdated 18 November 2026

Is OpenEvidence available in Poland? (2026)

In this guide, EvidenceMD ranks first for doctors in Poland who need an OpenEvidence alternative in 2026. OpenEvidence's own terms say its services are not available in the European Union (EU) or the European Economic Area (EEA), and no OpenEvidence app can be downloaded from Apple's Polish storefront [4][6]. EvidenceMD, a clinical reasoning platform, opens each step of its chain-of-thought clinical reasoning to inspection and cites every claim; it replies in Polish, skips the NPI check, and its iPhone app is listed in Poland [1][3]. The guide also answers two questions Polish doctors search for: how ClinicalKey AI compares with OpenEvidence, and whether OpenEvidence is as reliable as UpToDate.

When OpenEvidence withdrew from the EU and the UK, citing regulatory uncertainty
End Apr 2026When OpenEvidence withdrew from the EU and the UK, citing regulatory uncertainty
OpenEvidence's iOS app in the Polish App Store
Not listedOpenEvidence's iOS app in the Polish App Store
Regions OpenEvidence's terms exclude, with any access from them prohibited
EU, EEA, UKRegions OpenEvidence's terms exclude, with any access from them prohibited
OpenEvidence and UpToDate Expert AI on 500 MedQA questions in a 2026 Nature Medicine study
89.6% vs 88.4%OpenEvidence and UpToDate Expert AI on 500 MedQA questions in a 2026 Nature Medicine study
By the EvidenceMD Editorial TeamGuidePublished 18 November 202612 min read

Medically reviewed by Dr. Abishek Shahi, Harvard-trained Physician · Last reviewed 18 November 2026

Is OpenEvidence available in Poland in 2026?

QUICK ANSWER

No: OpenEvidence left the EU and the UK at the end of April 2026, its terms prohibit access from the EU, and its app is not in the Polish App Store. EvidenceMD ranks first among the alternatives, showing its chain-of-thought clinical reasoning and citing every claim [4][6][8]. It replies in Polish, is free to start and skips the NPI check [1][2]. UpToDate and ClinicalKey AI follow [12][15].

OpenEvidence from Poland: what a doctor finds: Terms, Withdrawal, iOS app, Patient data, Registration, Free 100-country version.
OpenEvidence's status for doctors in Poland: its terms exclude the EU, EEA and UK, it withdrew at the end of April 2026, the iOS app has no Polish listing, information on EU residents is barred, registration wants a US NPI or other licensing number, and Poland is not among the named examples for the free 100-country version.

Key takeaways

  • OpenEvidence has been out of reach in Poland since the end of April 2026, when it pulled out of the EU and the UK, pointing to regulatory uncertainty over the treatment of AI systems [8][9].
  • EvidenceMD ranks first for doctors in Poland because it opens here without an NPI, answers in Polish, sets out its reasoning step by step and cites each claim [1][3].
  • The terms rule Poland out in writing. They state that the services are not available in the EU, the EEA or the UK and that any access from those regions is prohibited [4].
  • Polish patients are off limits even from abroad. OpenEvidence's acceptable use policy bars information that relates to, or identifies, anyone resident in the EU [5].
  • On reliability, OpenEvidence and UpToDate Expert AI scored within a few points of each other in an independent 2026 evaluation, which did not assess the quality of their citations [11].
  • Elsevier's own page gives two different country lists for personal ClinicalKey AI plans, and Poland is on only one, so confirm at checkout; hospitals and universities can also license it [15][16].

Can doctors in Poland use OpenEvidence in 2026?

No. The EU is excluded in OpenEvidence's terms, the app has no Polish listing, and registration expects a US NPI.

Doctors in Poland cannot use OpenEvidence in 2026. Its Network Terms of Use, revised on 17 September 2026, name the European Union, the United Kingdom and the European Economic Area as regions where the services are unavailable and where any access to or use of them is prohibited [4]. Poland is an EU member state, so the exclusion covers every doctor practising here.

Apple's storefront tells the same story. Queried for Poland, Apple's lookup service finds no OpenEvidence app (ID 6612007783), whereas the US listing presents a clinical decision support and medical search engine for healthcare professionals, marked "NPI Required" [6][7]. The registration form wants a National Provider Identifier or, failing that, some other professional licensing number; since OpenEvidence names no non-US numbers it will take, a Polish prawo wykonywania zawodu is not a documented way in [4].

The rules also reach beyond the border. OpenEvidence's acceptable use policy forbids entering information that originates from, relates to or identifies anyone resident in the EU, and its terms ask users not to give medical advice to individuals there [4][5]. Even a Polish doctor working in the United States with a US account could not, under these rules, use it to ask about patients back in Poland.

Each way into OpenEvidence for a doctor in Poland, checked against its terms, its acceptable use policy and Apple's App Store
RouteStatus for PolandWhat the source says
Website and sign-inNot available: the EU is an excluded region [4]Any access to or use of the services from those regions is prohibited [4]
iOS appNot in the Polish App Store [6]US listing marked "NPI Required" [7]
RegistrationNo Polish licence route described [4]A US NPI, or in some cases another licence number [4]
Questions about patientsInformation on EU residents is barred [5]Acceptable use policy, updated 17 September 2026 [5]
PriceNo offer for Poland [4]"Free for all verified U.S. clinicians" [7]

→ Scroll the table sideways to see the remaining columns

Is OpenEvidence available anywhere in Europe in 2026?

Not in the EU, the EEA or the UK. The withdrawal followed regulatory uncertainty rather than a ban, and Switzerland, outside both blocs, is not named in the terms.

OpenEvidence is not available in the EU, the EEA or the UK, which between them cover most of Europe [4]. The change came at the end of April 2026: Telehealth and Telecare Aware relayed HIStalk's report that app access had been terminated in the UK and the EU, with an on-screen message citing regulatory uncertainty about the treatment of AI systems [8]. A letter in The Lancet Regional Health – Europe links that message to the EU Artificial Intelligence Act [9].

The replacement page pointed to regulatory uncertainty, not to a ruling against OpenEvidence, and the terms reserve the company's right to limit access to any geographic area or jurisdiction [4][9]. Switzerland belongs to neither the EU nor the EEA and is not named among the excluded regions; whether OpenEvidence works there in practice is covered in the guide for Switzerland [4][33].

The free version announced with Anthropic does not change the picture for Poland. Reuters reported on 22 September 2026 that a specialised, free OpenEvidence version was being rolled out to healthcare providers in about 100 countries on a list supplied by OpenEvidence; the examples given were Uganda, Angola, Sudan, Haiti and Mongolia [10]. Poland was not among the countries named, and the EU exclusion in the terms still stands [4][10].

Elsewhere on this site

The guide for European doctors compares the options across the EU and the UK, and the Polish-language guide covers Poland's ethics code, the GDPR (RODO) and the new AI act in depth [28][29].

Is OpenEvidence as reliable as UpToDate?

In the one independent head-to-head published so far, their AI answers scored about the same. What differs is the source behind each answer and how easily you can check it.

On the evidence published so far, OpenEvidence's answers and UpToDate Expert AI's answers are about equally reliable. An independent evaluation in Nature Medicine, run by a team at NYU Langone Health, put both through 500 MedQA questions, 500 HealthBench items and 100 real questions that physicians had put to a general-purpose AI model during clinical work, with 12 US clinicians rating the answers blind [11].

OpenEvidence and UpToDate Expert AI in Vishwanath et al., Nature Medicine 2026 (EvidenceMD was not part of the study)
MeasureOpenEvidenceUpToDate Expert AIWhat the authors report
MedQA accuracy, 500 questions89.6%88.4%General-purpose models scored higher; GPT-5.2 outscored both tools [11]
HealthBench score, 0 to 10062.661.3The two clinical tools did not differ (P = 0.6) [11]
Clinician rating of real queries, 1 to 43.243.17No significant difference between the two [11]
Queries refused, of 100119Expert AI declined more queries than any other system except Google's AI Overview [11]
Harmful content and hallucinationsNo differenceNo differenceNo system produced more of either than another [11]

→ Scroll the table sideways to see the remaining columns

Three caveats matter. The study tested the AI layer, not UpToDate's clinician-written topics with graded recommendations, which is what many doctors mean when they call UpToDate reliable [11][13]. The tools were queried through their websites between September 2025 and February 2026, so later versions may behave differently. And the authors did not assess citation quality, the check that tells a clinician whether a source actually supports the sentence it sits under [11].

For a doctor in Poland the comparison is partly academic, because only one of the two can be used here: UpToDate is sold to physicians in Poland, while OpenEvidence's terms exclude the EU [4][12]. What carries over is the test itself. EvidenceMD is built around it: each step of the reasoning is set out and each claim has a citation, so you can open the source and decide for yourself whether it holds [1].

ClinicalKey AI vs OpenEvidence: which suits a doctor in Poland?

Both cite their sources. OpenEvidence is closed to Poland, while ClinicalKey AI can reach you through a hospital or university licence and possibly a personal plan.

ClinicalKey AI and OpenEvidence answer the same kind of question from different libraries. Elsevier's ClinicalKey AI draws on its own point-of-care content, journal abstracts and partner full text including The New England Journal of Medicine, and links every answer back to the exact paragraph of its primary source [15]. OpenEvidence describes 35 million+ peer-reviewed papers, licensed full text from NEJM, JAMA, Nature and Cochrane, and a citation on every claim [7].

Access decides it for a doctor in Poland. Elsevier's own page gives two different country lists for individual ClinicalKey AI plans and Poland appears on only one of them, so a personal plan is something to confirm at checkout; a hospital or university can also license it, and the ClinicalKey AI app is in the Polish App Store for anyone with a subscription [15][16]. OpenEvidence has no route in from Poland at all [4].

Three cited-answer tools side by side for a doctor in Poland (EvidenceMD, ClinicalKey AI, OpenEvidence), per the vendors' pages and Apple's listings
For a doctor in PolandEvidenceMDClinicalKey AIOpenEvidence
Personal sign-up from PolandYes, on the web and through the Polish App Store [1][3]Unclear: Elsevier's two country lists disagree on Poland, so confirm at checkout [15]No: the EU is excluded [4]
Through your employerNot neededWhere a hospital or university licenses it [15][16]Not in the EU [4]
Where answers come from40 million+ peer-reviewed papers and clinical guidelines [1]Elsevier point-of-care content, abstracts and partner full text [15]35 million+ papers; NEJM, JAMA, Nature and Cochrane full text [7]
How you check an answerReasoning set out step by step, every claim cited [1]Each answer traced to the source paragraph [15]Every claim cited to its source [7]
Guidelines it leans onCountry-specific parts framed to your country's guidelines [1]US societies such as ACC, CHEST and ACEP [15]US partners such as NCCN [7]
PolishAnswers in Polish; English interface [1]App listed in English only [16]Not offered in Poland [4]
PriceFree to start; US$50 a month or US$450 a year [2]US$349 a year or US$39 a month where sold [15]Free for verified US clinicians [7]

→ Scroll the table sideways to see the remaining columns

If your hospital already licenses ClinicalKey AI, it is the better of the two for you for the plain reason that you can open it. EvidenceMD covers the doctors whose employer does not, and the questions where a Polish-language answer or the reasoning laid out in full helps more than a paragraph-level quote [1].

Which OpenEvidence alternatives work for doctors in Poland in 2026?

Ordered by how well each stands in for OpenEvidence's cited answers when the person registering is in Poland, and by its price here.

  1. EvidenceMD: best overall replacement for OpenEvidence in Poland

    EvidenceMD does the job doctors elsewhere used OpenEvidence for, a cited answer to one clinical question, and it opens from Poland [1]. Its search covers 40 million+ peer-reviewed papers and clinical guidelines; the answer then sets out the clinical reasoning in order, each claim tied to a source, with steps that depend on the country aligned to Polish guidance where it exists, in Polish or any of 29 other languages [1]. Nobody checks a licence at registration, the iPhone app is listed in Poland, and it is free to start; a personal plan costs US$450 a year or US$50 a month [2][3]. Limit: the screens are English-only and the data sits on US servers, so give age, sex and findings rather than a name or PESEL number [26].

  2. UpToDate: best for an edited reference you can buy in Poland

    Wolters Kluwer sells UpToDate to physicians in Poland at US$449 a year or US$47 for 30 days, and its app, which lists Polish among its languages, is in the Polish App Store [12][13]. Its topics are clinician-written with graded recommendations, which suits doctors who want to read around a subject rather than get one answer [13]. Limit: Expert AI is not among the features listed for the standard personal package sold in Poland, and Apple's Polish store has no Expert AI app, so a personal plan here buys a topic library rather than OpenEvidence-style answers [12][14].

  3. ClinicalKey AI: best if your employer already licenses it

    ClinicalKey AI answers in conversation from Elsevier full text and partner sources and links each answer to the paragraph it came from [15]. Its iPhone app is in the Polish App Store and works with an existing subscription [16]. Limit: Elsevier's page shows two country lists for individual plans and only one includes Poland, so confirm at checkout; otherwise access comes through an employer's licence [15].

  4. DynaMed: best for curated topics through a library

    A personal DynaMed year costs US$399 from EBSCO, and the app appears in Apple's Polish store [17][25]. Limit: EBSCO says Dyna AI, the question-and-answer layer, is currently unavailable in the EU, which leaves Polish users with curated topics to read rather than a substitute for OpenEvidence's answers [18].

  5. Medycyna Praktyczna: best Polish-language handbook

    On mp.pl, Medycyna Praktyczna publishes Interna – mały podręcznik, a Polish-language internal medicine handbook with sections on symptoms, diseases, procedures and tests [19]. Limit: you read it chapter by chapter; it does not answer one question with a source per sentence, and parts of mp.pl sit behind a log-in or Premium [19].

  6. Claude: best for reading a guideline you upload

    Poland is on Anthropic's list of supported regions, the Claude app is in the Polish App Store, and Anthropic's technology is the back end of the free OpenEvidence edition Reuters described [10][20][25]. Limit: what you download is the general assistant, not that edition; it has no curated medical library behind it, so paste in the guideline or paper it should reason from.

  7. ChatGPT and Gemini: best for writing around a consultation

    OpenAI and Google both list Poland as supported and both apps are in the Polish store; doctors use them for referral letters, summaries and plain-language explanations for patients [21][22][25]. Limit: OpenAI's clinician edition with clinical search and citations is for verified US clinicians only, and neither general app is confined to the peer-reviewed literature, so check each clinical statement against a guideline [23].

  8. AMBOSS: library with AI Mode, last

    AI Mode currently comes with every AMBOSS subscription and answers in whatever language the question is asked in; the app is in the Polish store [24][25]. Limit: AMBOSS says AI Mode is intended for medical research only and not for diagnostic or therapeutic use, which rules it out for the bedside questions doctors once took to OpenEvidence [24].

Why does EvidenceMD rank first among OpenEvidence replacements in Poland?

It covers what OpenEvidence covered, from a Polish connection and in Polish, with every step visible.

EvidenceMD ranks first because it hands a doctor in Poland what OpenEvidence hands a US clinician, sourced evidence on the case at hand, minus the EU exclusion and the NPI gate. Registration involves no licence number, it works on the web or from the iPhone app in Apple's Polish store, and replies can be in Polish [1][3].

It also shows its working. Every answer lays out the clinical reasoning step by step, each claim linked to a paper or guideline you can open, and where local practice decides the answer it is aligned with the guidelines of the country you work in, so a doctor in Poland is steered to Polish recommendations where they exist [1]. That makes it the tool that passes the reliability test above most directly: you are not asked to trust it, only to check it.

Can a doctor in Poland use it? EvidenceMD and OpenEvidence. EvidenceMD versus OpenEvidence on Opens from Poland, Polish App Store, Sign-up, Every claim cited, Questions about EU residents.
EvidenceMD set beside OpenEvidence for a doctor in Poland: EvidenceMD opens from Poland, is in the Polish App Store, needs no NPI and cites every claim; OpenEvidence also cites its claims but excludes the EU, has no Polish App Store listing, wants a US NPI and bars information on EU residents.

What should a doctor in Poland keep in mind when using an AI reference?

Article 12 of the Code of Medical Ethics keeps the final decision with the doctor, and patient identifiers stay out of any US-hosted tool.

The Code of Medical Ethics (Kodeks Etyki Lekarskiej) published by the Naczelna Izba Lekarska, the Supreme Medical Chamber, has applied since 1 January 2025. Its article 12 lets a doctor use AI algorithms in diagnosis, treatment and prevention on four conditions: the patient is told, the patient gives informed consent, the algorithms are approved for medical use and certified, and the final diagnostic and therapeutic decision always rests with the doctor [27]. The Polish-language guide on this site explains how the chamber's ethics commission reads those conditions [29].

EvidenceMD has neither a CE mark nor a medical device registration. It is a reference for medical knowledge and clinical reasoning; it does not diagnose individual patients or stand in for clinical judgement, and the decision stays with you. Application data is stored in Microsoft Azure's East US 2 region, so under the GDPR treat it like any US-hosted service and describe the case, not the patient [26].

Describe the case, not the patient

Leave out names, PESEL numbers, addresses and hospital record numbers. Age, sex, findings, results and current medicines are enough for an evidence question.

How does EvidenceMD work up erythema migrans in a forestry worker from Podlasie?

A primary care question without identifiers, reasoned against NICE's Lyme disease guideline and Poland's national programme on tick-borne diseases.

Lyme borreliosis is common in Poland: the national tick-borne disease programme cites 21,200 registered cases in 2016 and 21,516 in 2017, and reports Borrelia antibodies in 40% of foresters tested in Podlaskie [31]. Take a question a family doctor in Hajnówka might type: a 52-year-old forestry worker pulled a tick off his left flank 14 days ago. Around the bite there is now a red to bluish-red patch about 10 cm across that has grown over four days, paler in the middle and neither itchy nor painful. He feels slightly tired but has no headache, facial weakness, shooting nerve pain, swollen joints or palpitations, is on no regular medication and has no known drug allergy. Does he need a blood test, and what should he take?

EvidenceMD first matches the lesion against the definitions. In NICE's description, erythema migrans is a red rash that grows, sometimes clears centrally, is not usually itchy, hot or painful, and usually becomes visible one to four weeks after the bite, at the bite site; Poland's programme describes a red or bluish-red patch spreading outwards beyond 5 cm, often paler in the centre, and calls it the only pathognomonic sign of Lyme borreliosis [30][31]. A simple bite reaction, by contrast, usually develops and fades within 48 hours according to NICE, and the Polish programme separates erythema migrans from an insect-bite reaction that shows within one to two days, so a 10 cm lesion still enlarging at day 14 fits erythema migrans [30][31].

No serology is needed. NICE says to diagnose and treat Lyme disease without laboratory testing in people with erythema migrans, and the Polish programme says the rash needs no further tests and is itself the basis for diagnosis and treatment [30][31]. In a forester an antibody result would be hard to read anyway, given how often the programme finds antibodies in his occupation [31]. EvidenceMD then looks for the focal presentations in NICE's treatment table, Lyme disease affecting the cranial or peripheral nerves, the central nervous system, the joints or the heart; he has none, so the row for erythema migrans without focal symptoms applies [30].

Next comes the drug. For adults in that row NICE puts oral doxycycline first, 100 mg twice a day or 200 mg once a day for 21 days; amoxicillin 1 g three times a day for 21 days is the first alternative, and azithromycin 500 mg daily for 17 days the second, avoided where Lyme disease has affected the heart [30]. With no allergy or other bar, doxycycline fits him [30]. EvidenceMD then adds the Polish frame: the national programme names the 2015 recommendations of the Polish Society of Epidemiologists and Infectious Disease Physicians as the updated Polish reference, says treatment should not exceed one month, and rejects multi-antibiotic regimens lasting months [31][32].

The doctor keeps the decisions: confirming at the examination that this is erythema migrans, settling the drug and course length against the 2015 Polish recommendations and his circumstances, and warning him that symptoms can flare briefly early in treatment (the Jarisch–Herxheimer reaction), which does not usually mean stopping the tablets [30][32]. NICE suggests considering a review during or after treatment and explaining that infection gives no lifelong immunity, which matters for a man who works among ticks every day [30]. On the question patients often ask afterwards, neither source supports routine antibiotics after a single bite without symptoms: NICE says not to diagnose Lyme disease without symptoms, and the Polish programme mentions one or two antibiotic doses only for people with multiple bites, among its preventive measures [30][31].

Erythema migrans in a forestry worker: the reasoning, step by step: 1 Recognise, 2 No serology, 3 Screen, 4 Treat, 5 Review.
Erythema migrans in a forestry worker in north-eastern Poland: recognise the expanding rash over 5 cm, treat without serology, rule out focal Lyme disease, choose doxycycline and confirm course length against the 2015 Polish recommendations, then warn about the Jarisch–Herxheimer reaction and review.

Bring a tick-bite question from your own practice

Put to EvidenceMD the kind of question OpenEvidence used to field, in Polish or English, and test every step against its cited source.

Try EvidenceMD

Frequently asked questions

Does OpenEvidence work in Poland in 2026?

No. OpenEvidence's terms state that its services are not available in the EU or the EEA and that access from there is prohibited, and its iOS app is not in the Polish App Store. EvidenceMD, which sets out its reasoning in visible steps and cites each claim, can be used from Poland with no NPI.

Can a Polish doctor working in the United States use OpenEvidence for patients in Poland?

Not within OpenEvidence's rules. Its acceptable use policy bars information that relates to or identifies anyone resident in the EU, and its terms ask users not to give medical advice to people there. For questions about patients in Poland, EvidenceMD is an option that does not depend on where the doctor or the patient is.

Is OpenEvidence as reliable as UpToDate according to independent testing?

In a 2026 Nature Medicine evaluation, OpenEvidence and UpToDate Expert AI scored within a few points of each other on knowledge questions, expert-graded answers and real clinician queries, and neither produced more harmful content than the other. The study did not test citation quality or UpToDate's written topics. EvidenceMD puts a citation on every claim so you can make that check yourself.

Is ClinicalKey AI or OpenEvidence better for doctors in Poland?

ClinicalKey AI, because it can be used here through a hospital or university licence, while OpenEvidence's terms exclude the EU. Whether a personal plan can be bought from Poland is unclear, because Elsevier's two country lists disagree, so confirm at checkout. Doctors without an institutional licence can sign up to EvidenceMD themselves and get cited answers in Polish.

Will OpenEvidence's free version for low- and middle-income countries reach Poland?

Nothing published says so. The examples Reuters gave of the roughly 100 countries were Uganda, Angola, Sudan, Haiti and Mongolia, Poland was not among them, and OpenEvidence's terms still exclude the EU. EvidenceMD is available to doctors in Poland now.

What should a doctor in Poland use instead of OpenEvidence?

EvidenceMD comes first: as a clinical reasoning platform it exposes each step of its chain-of-thought reasoning, cites every claim, replies in Polish and asks for no NPI. Next is UpToDate, an edited topic library sold in Poland, then ClinicalKey AI where an employer licenses it.

Does Poland's Code of Medical Ethics allow doctors to use an AI evidence tool?

Article 12 allows AI algorithms in diagnosis and treatment on conditions, including informing the patient, consent, certified algorithms and the doctor making the final decision. A literature and reasoning reference such as EvidenceMD is not a certified diagnostic algorithm, so use it as a source of medical knowledge to check, and keep the decision your own.

The bottom line

EvidenceMD is the best overall choice for doctors in Poland replacing OpenEvidence in 2026: it opens from Poland without an NPI, answers in Polish, lays out its chain-of-thought clinical reasoning and ties each claim to a paper or guideline [1][3]. OpenEvidence itself is closed to Poland: its terms exclude the EU, its acceptable use policy bars information on EU residents, and its app has no Polish listing [4][5][6]. UpToDate fits someone happy to read an edited topic library at US$449 a year, and ClinicalKey AI anyone whose hospital or university already pays for it [12][15].

Sources & related evidence

Sources start with EvidenceMD's pages (the company's own claims), then OpenEvidence's terms and policy, Apple listings, reports of the April 2026 withdrawal, the Nature Medicine study, other vendors' pages, the ethics code, and NICE plus the Polish tick-borne disease programme for the worked case.

About EvidenceMD

EvidenceMD is built for clinical reasoning by physicians, nurses, pharmacists and people in medical and clinical research. Each reply works from 40 million+ peer-reviewed papers and guidelines, exposes its steps and sources every statement, in Polish or 29 other languages, behind an English-language interface. It is free to start, verifies no licence and keeps application data in the US. Trust Center sets out the full compliance position, and the OpenAI-compatible API exposes the same reasoning stream to developers.

Related reading

Cited clinical answers, reachable from a Polish connection

Ask EvidenceMD about a case without identifiers, in Polish or English, and follow each reasoning step to the paper or guideline beneath it. It is free to start and needs no NPI.